Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
sabato, novembre 21
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Neurocrine Biosciences Inc
NBIX
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$150.57
-6.02
-3.84%
In chiusura: Nov 20, 4:00 PM EST
$150.57
N/A
Post-mercato: Nov 20, 4:00 PM EST
Get Report
Panoramica
Notizie
Grafici
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Neurocrine Biosciences Financials
Neurocrine Biosciences (NBIX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
Nasdaq 100 Gets a Lift As Nvidia Overtakes Apple: Stock Market Today
Apple's memory-cost margin warning hands Nvidia the top market value as chipmakers rebound. Here's what's happening in the stock market today.
Piero Cingari
PRO
Neurocrine Biosciences Raises FY 2026 INGREZZA Net Product Sales Guidance from $2.825B-$2.875B to $2.900B-$2.925B
Neurocrine Biosciences (NASDAQ:NBIX) Raises FY 2026 INGREZZA Net Product Sales Guidance from $2.825B-$2.875B to $2.900B-$2.925B
Benzinga Newsdesk
PRO
Neurocrine Biosciences Q3 Adj. EPS $3.29 Beats $1.91 Estimate, Sales $1.119B Beat $1.043B Estimate
Neurocrine Biosciences (NASDAQ:NBIX) reported quarterly earnings of $3.29 per share which beat the analyst consensus estimate of $1.91 by 72.25 percent. This is a 51.61 percent increase over earnings of $2.17 per share
Benzinga Newsdesk
Apple, Palantir On Deck Monday As AI Demand, iPhone Growth Face Test
Apple headlines Monday’s reports, with investors looking for continued iPhone momentum and evidence that its artificial-intelligence push can support the company’s next leg of growth. Marriott International, Entergy,
Benzinga Insights
PRO
Neurocrine Biosciences Q2 Adj. EPS $2.85 Beats $1.34 Estimate, Sales $959.000M Beat $883.259M Estimate
Neurocrine Biosciences (NASDAQ:NBIX) reported quarterly earnings of $2.85 per share which beat the analyst consensus estimate of $1.34 by 112.69 percent. This is a 72.73 percent increase over earnings of $1.65 per share
Benzinga Newsdesk
PRO
Neurocrine Biosciences Q1 Adj. EPS $1.94 Beats $1.61 Estimate, Sales $814.500M Beat $763.112M Estimate
Neurocrine Biosciences (NASDAQ:NBIX) reported quarterly earnings of $1.94 per share which beat the analyst consensus estimate of $1.61 by 20.5 percent. This is a 177.14 percent increase over earnings of $0.70 per share
Benzinga Newsdesk